News & Media
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.
Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World
iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs
iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM will produce and supply Good Manufacturing Practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE’s future clinical studies to enable development of iECURE’s programs with the shared mission of accelerating the availability of these potential treatments to the patients.
Strategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy King of Prussia
Center for Breakthrough Medicines Launches Analytical Testing Services for Advanced Therapies, Bringing Solutions to a Supply-Constrained Industry
Testing Business Unit Will Grow to More Than 400 Employees, Eliminate Wait Times, and Enable Faster Release Times…
The Center for Breakthrough Medicines and the University of Pennsylvania Partner in the Manufacturing of Gene Therapies
— Penn’s Innovation in Process Science Combines with CBM Manufacturing Capability to Develop Large-Scale Gene Therapy…